SAVE THE DATE:
You and your endocrinology and diabetes specialist colleagues are invited to

An EASD  2024 CME Expert Board Satellite Symposium on

Early Use of CGM in Type 2 Diabetes
Late-Breaking Trials on CGM-Directed Glycemic Management, Patient 
Safety, and Resource Utilization Across the Spectrum of Diabetes Care
main image

Save the Date and Time
Register Now!

Monday, September 9, 2024

Registration and Lunch: 10:00 hrs
CME Presentation: 10:30–12:00 hrs
Sydney Hall

Enrollment for this
Symposium is
complimentary

Save the Date and Time – Register Now!

Monday, September 9, 2024
Registration and Lunch: 10:00 hrs
CME Presentation: 10:30 hrs – 12:00 hrs
Location: Sydney Hall

Brochure Cover

For more information:
  info@cmeducation.net

Program Agenda


10:30 hrs – 10:55 hrs

Chair’s Introduction

Applying CGM to Improve Glycemic Control with AID Systems in Type 1 Diabetes

Interactive Case Study: Leveraging CGM Technology to Optimize Glycemic Metrics

F. Javier Ampudia-Blasco, MD PhD – Program Chair
Endocrinologist
Dep. Endocrinology & Nutrition
Clinic University Hospital Valencia
Valencia, Spain



10:55 hrs – 11:20 hrs

The Power of CGM as a Lifestyle Intervention Platform

Interactive Case Study: Deploying the AGP Report to Engage and Motivate

Richard Bergenstal, MD
Executive Director
Park Nicollet International Diabetes Center
Adjunct Professor, Department of Medicine
University of Minnesota
St. Louis Park, MN





11:20 hrs – 11:45 hrs

CGM-Based Roadmaps for Reducing Hospitalizations and CV Mortality in T2D

Interactive Case Study: Improving Clinical Outcomes in Vulnerable Persons

Ramzi Ajjan, MD, FRCP, MMed.Sci, PhD
Professor of Metabolic Medicine
University of Leeds and
Leeds Teaching Hospitals Trust
United Kingdom


11:45 hrs – 12:00 hrs 

Interactive iQ&A Session

Moderated by Program Faculty


Program Chair and Distinguished Faculty

F. Javier Ampudia-Blasco, MD, PhD
— Program Chair

Endocrinologist

Deptartment of Endocrinology & Nutrition

Clinic University Hospital Valencia

Valencia, Spain

Richard Bergenstal, MD  

Executive Director

Park Nicollet International Diabetes Center

Adjunct Professor, Department of Medicine

University of Minnesota

St. Louis Park, MN

Western University

London, Ontario, Canada

Ramzi Ajjan, MD, FRCP,
MMed.Sci, PhD

Professor of Metabolic Medicine

University of Leeds and Leeds Teaching Hospitals Trust

United Kingdom



Enrollment for this
Symposium is
complimentary


EDUCATIONAL AND LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

  • Outline and discuss the evidentiary basis for sensor-based CGM technologies, and how to best Implement CGM-based technologies into their overall diabetes care plans for persons with T2D and T1D within the diabetes and endocrinology specialty setting.
  • Analyze the rationale and evidence for recommending and facilitating adoption of technology-centric CGM monitoring and treatment plans using patch-and-reader-based technologies.
  • Compare and contrast available CGM-facilitating monitoring technologies and pair such technologies with optimal patient profiles.
  • Educate persons with diabetes about the rationale, evidence, and outcome- optimizing results associated with technology-based, patient-centric and physician-directed CGM monitoring strategies that can be used to effect optimal lifestyle, diet-, and pharmacology-based approaches to attaining guideline-based HA1c levels in persons with T2D and T1D.
  • Identify which persons with diabetes are ideal candidates for a technology-based, patient-directed glucose monitoring system.
  • Interpret and apply data and results from clinical trials in CGM-facilitating monitoring technologies to improve patient care, improve safety of drug therapy for T2D and T1D, detect and mitigate risk of hypoglycemia, improve patient- and physician-directed changes in antidiabetic therapy, reinforce the safe use of antidiabetic drugs, and facilitate patient-activated drug titration, glycemic monitoring and disease management.
  • Translate landmark clinical studies focused on CGM-based technologies to the front lines of clinical practice in the diabetes and primary care; and understand the translational implications of deploying sensor-based CGM technologies as a foundational approach to improving outcomes in patients across the spectrum of diabetes.

TARGET AUDIENCE — WHO SHOULD ATTEND

This Clinical Excellence Summit is directed at the following: diabetes and endocrinology specialists and researchers and related healthcare providers who manage patients with Type 2 or Type 1 diabetes.

GRANTOR SUPPORT

Supported by an educational grant from Abbott Diabetes Care.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Chan Medical School and CMEducation Resources, LLC. The University of Massachusetts Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The University of Massachusetts Chan Medical School designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

FACULTY & PROVIDER DISCLOSURE

It is the policy of the University of Massachusetts Chan Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Chan Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

———